Palm Springs, Calif.—Naldemedine treatment for 12 weeks significantly relieved opioid-induced constipation (OIC) compared with placebo, as shown by a greater proportion of responders with spontaneous bowel movements (SBMs). According to data from the Phase III, randomized, double-blind, placebo-controlled trial, naldemedine was also well tolerated relative to placebo.
“This study demonstrated that naldemedine works peripherally, improving opioid-induced constipation with a good